Article metrics

Download PDFPDF

507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to January 2024

AbstractFullPdf
Nov 2021374016
Dec 20217808
Jan 20228007
Feb 20224203
Mar 202216603
Apr 202284011
May 20225007
Jun 202211609
Jul 20224208
Aug 202286012
Sep 2022962051
Oct 2022440032
Nov 2022104015
Dec 202290011
Jan 20235406
Feb 20237208
Mar 20236008
Apr 202352017
May 20234603
Jun 20236007
Jul 202384011
Aug 202382016
Sep 20234605
Oct 20235407
Nov 2023132011
Dec 20239004
Jan 20243000
Total35760296